BWX Technologies, Inc. BWXT is broadening its commercial nuclear portfolio through expanded capabilities in nuclear medicine and medical radioisotopes. The company's acquisition of Kinectrics in May 2025 added capabilities in the production and supply of isotopes for the radiopharmaceutical industry, enabling BWXT to expand its presence across both nuclear power and nuclear medicine markets.
BWX Technologies’ commercial operations segment already provides products for diagnostic imaging and radiotherapeutic treatments, including medical radioisotopes, radiopharmaceuticals and medical devices. These capabilities give the company exposure to healthcare applications that rely on specialized nuclear materials and technologies.
The Kinectrics acquisition also strengthens BWX Technologies’ ability to serve customers across the nuclear medicine value chain. Kinectrics has capabilities spanning isotope production and supply, while BWX Technologies’ existing commercial operations include partnerships with life science and pharmaceutical companies. This combination expands the company's commercial reach beyond traditional nuclear energy applications.
Demand for critical medical radioisotopes and radiopharmaceuticals provides another avenue for BWX Technologies to leverage its nuclear expertise. As the company integrates Kinectrics' capabilities, its broader presence across nuclear medicine could diversify its commercial operations while creating opportunities in specialized healthcare markets.
Companies Expanding Nuclear Medicine Capabilities
The nuclear medicine industry continues advancing radiopharmaceutical and diagnostic imaging capabilities to support growing demand for specialized medical applications. Companies like Cardinal Health, Inc. CAH and GE HealthCare Technologies Inc. GEHC are also expanding their presence across the nuclear medicine and medical imaging markets.
Cardinal Health operates nuclear pharmacies and radiopharmaceutical manufacturing facilities, supporting the preparation, production and distribution of products used in nuclear medicine.
GE HealthCare provides medical imaging and diagnostic pharmaceutical technologies that support nuclear medicine workflows and broader diagnostic applications.
Earnings Estimates for BWXT Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 18.45% and 10.52%, respectively.
Image Source: Zacks Investment Research
BWXT Stock Trading at a Discount
BWX Technologies is trading at a discount relative to the industry, with a forward 12-month price-to-sales of 3.94X compared with the industry average of 8.65X.
Image Source: Zacks Investment Research
BWXT Stock Price Performance
Over the past year, BWXT shares have fallen 1.2% against the industry’s 13.9% growth.
Image Source: Zacks Investment Research
BWXT’s Zacks Rank
BWX Technologies currently sports a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BWX Technologies, Inc. (BWXT): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).